Article Details
Retrieved on: 2020-12-06 23:37:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Older patients with relapsed/refractory indolent non-Hodgkin lymphoma (<b>NHL</b>) benefited from lenalidomide plus rituximab (R<sup>2</sup>); they saw a benefit that ...
Article found on: www.cancertherapyadvisor.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here